Acute Interstitial Nephritis With Karyomegalic Epithelial Cells After Nivolumab Treatment—Two Case Reports

Acute Interstitial Nephritis With Karyomegalic Epithelial Cells After Nivolumab Treatment—Two Case Reports

Clinical application of immune checkpoint inhibitors (CPIs) including nivolumab is expanding in the field of oncology treatment. Nivolumab is an anti-programmed death 1 protein (PD-1) antibody designed to augment an immunologic reaction against cancer cells. On the contrary, CPIs are known to cause...

Full description

Bibliographic Details
Main Authors: Masaki Ryuzaki, Hirobumi Tokuyama, Kiyotaka Uchiyama, Hideaki Nakaya, Kazuhiro Hasegawa, Kazutoshi Miyashita, Kohnosuke Konishi, Akinori Hashiguchi, Shu Wakino, Hiroshi Itoh
Format: Article
Language:English
Published: SAGE Publishing 2019-06-01
Series:Clinical Medicine Insights: Case Reports
Online Access:https://doi.org/10.1177/1179547619853647

Internet

https://doi.org/10.1177/1179547619853647

Similar Items